APA (7th ed.) Citation

Moore, K., Bookman, M., Sehouli, J., Miller, A., Anderson, C., Scambia, G., . . . Pignata, S. (2020). LBA31 Primary results from IMagyn050/GOG 3015/ENGOT-OV39, a double-blind placebo (pbo)-controlled randomised phase III trial of bevacizumab (bev)-containing therapy +/- atezolizumab (atezo) for newly diagnosed stage III/IV ovarian cancer (OC). Annals of Oncology, 31, S1161. https://doi.org/10.1016/j.annonc.2020.08.2261

Chicago Style (17th ed.) Citation

Moore, K.N, et al. "LBA31 Primary Results from IMagyn050/GOG 3015/ENGOT-OV39, a Double-blind Placebo (pbo)-controlled Randomised Phase III Trial of Bevacizumab (bev)-containing Therapy +/- Atezolizumab (atezo) for Newly Diagnosed Stage III/IV Ovarian Cancer (OC)." Annals of Oncology 31 (2020): S1161. https://doi.org/10.1016/j.annonc.2020.08.2261.

MLA (9th ed.) Citation

Moore, K.N, et al. "LBA31 Primary Results from IMagyn050/GOG 3015/ENGOT-OV39, a Double-blind Placebo (pbo)-controlled Randomised Phase III Trial of Bevacizumab (bev)-containing Therapy +/- Atezolizumab (atezo) for Newly Diagnosed Stage III/IV Ovarian Cancer (OC)." Annals of Oncology, vol. 31, 2020, p. S1161, https://doi.org/10.1016/j.annonc.2020.08.2261.